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The Right Ventricular Failure Risk Score
A Pre-Operative Tool for Assessing the Risk of Right
Ventricular Failure in Left Ventricular Assist Device Candidates
Jennifer Cowger Matthews, MD,* Todd M. Koelling, MD,* Francis D. Pagani, MD, PHD,†
Keith D. Aaronson, MD, MS*
Ann Arbor, Michigan
Objectives This study sought to develop a model that estimates the post-operative risk of right ventricular (RV) failure in left
ventricular assist device (LVAD) candidates.
Background Right ventricular failure after LVAD surgery is associated with increased morbidity and mortality, but identifying
LVAD candidates at risk for RV failure remains difficult.
Methods A prospectively collected LVAD database was evaluated for pre-operative clinical, laboratory, echocardiographic,
and hemodynamic predictors of RV failure. Right ventricular failure was defined as the need for post-operative
intravenous inotrope support for 14 days, inhaled nitric oxide for 48 h, right-sided circulatory support, or hos-
pital discharge on an inotrope. An RV failure risk score (RVFRS) was created from multivariable logistic regres-
sion model coefficients, and a receiver-operating characteristic curve of the score was generated.
Results Of 197 LVADs implanted, 68 (35%) were complicated by post-operative RV failure. A vasopressor requirement
(4 points), aspartate aminotransferase 80 IU/l (2 points), bilirubin 2.0 mg/dl (2.5 points), and creatinine
2.3 mg/dl (3 points) were independent predictors of RV failure. The odds ratio for RV failure for patients with
an RVFRS 3.0, 4.0 to 5.0, and 5.5 were 0.49 (95% confidence interval [CI] 0.37 to 0.64), 2.8 (95% CI 1.4 to
5.9), and 7.6 (95% CI 3.4 to 17.1), respectively, and 180-day survivals were 90  3%, 80  8%, and 66  9%,
respectively (log rank for linear trend p  0.0045). The area under the receiver-operating characteristic curve for
the RVFRS (0.73  0.04) was superior to that of other commonly used predictors of RV failure (all p  0.05).
Conclusions The RVFRS, composed of routinely collected, noninvasive pre-operative clinical data, effectively stratifies the risk
of RV failure and death after LVAD implantation. (J Am Coll Cardiol 2008;51:2163–72) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.009f
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right ventricular (RV) failure is a major cause of morbidity
nd mortality in patients who have undergone placement of
left ventricular assist device (LVAD). Right ventricular
ailure results in poor filling of the left ventricle (LV) and
oor LVAD output, often necessitating additional RV
upport in the form of inotropes or a right-sided mechanical
evice. When RV failure occurs, the perioperative mortality
f LVAD surgery increases to 19% to 43% (1–3) and
atients tend to have worse survival to (1,2,4–6) and after
7) cardiac transplant. Likewise, RV failure leads to in-
reased morbidity, including delayed rehabilitation, in-
reased transfusion requirements, and delayed or failed
estoration of end-organ function (2,4). Thus, a pre-
perative tool for identifying LVAD candidates at high risk
or RV failure would be valuable.
rom the *Division of Cardiovascular Medicine and †Section of Cardiac Surgery,
niversity of Michigan Health System, Ann Arbor, Michigan.u
Manuscript received August 20, 2007; revised manuscript received February 7,
008, accepted March 4, 2008.The complex pathophysiology of post-operative RV
ailure—RV myocardial dysfunction, ventricular interde-
endence, and elevated RV afterload—makes it difficult to
redict. Previously identified univariable predictors of RV
ailure have been prognostically inconsistent when evaluated
n independent samples (1,2,4–12). Using a large LVAD
atabase, we evaluated over 80 pre-operative variables to
dentify independent predictors of RV failure. We then
reated a right ventricular failure risk score (RVFRS) to
etter stratify RV failure risk in LVAD candidates.
ethods
prospectively collected database of patients receiving an
VAD at the University of Michigan between October
996 and August 2006 was evaluated. A retrospective
nalysis of pre-operative clinical, echocardiographic, labo-
atory, and hemodynamic data was performed to determine
isk for RV failure after LVAD implantation. Right ventric-
lar failure was defined prospectively as the post-operative need
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Predicting Right-Sided Failure in LVAD Candidates June 3, 2008:2163–72for: 1) intravenous inotrope sup-
port for 14 days (1,2,12); 2) in-
haled nitric oxide (iNO) for 48
h; 3) right-sided circulatory sup-
port (extracorporeal membrane
oxygenation [ECMO] or right
ventricular assist device [RVAD]);
or 4) hospital discharge with an
intravenous inotrope. The deci-
sion to implement each of these
interventions was based on signs
of clinically significant RV dys-
function and was at the discre-
tion of the treating physician.
Data from patients with temporary
right-sided circulatory support
(ECMO or an extracorporeal
RVAD) placed before LVAD im-
plant were included in the primary
analyses.
Variables evaluated. Clinical
data evaluated included demo-
graphics; the occurrence of a pre-
operative myocardial infarction,
arrest, or post-cardiotomy shock;
the need for life support, includ-
ing mechanical ventilation, renal
replacement therapy, or tempo-
rary LV mechanical bridge (de-
ned as a Tandem Heart [CardiacAssist Inc., Pittsburgh,
ennsylvania], ECMO, or Abiomed BVS-5000 [Abiomed
nc., Danvers, Massachusetts]); or the requirement for
re-operative intra-aortic balloon pump or continuous in-
ravenous inotrope (milrinone, dobutamine, or dopamine),
asopressor (norepinephrine, vasopressin, or phenyleph-
ine), or antiarrhythmic therapies immediately before
VAD placement.
Echocardiograms were obtained in 193 patients (98%)
efore LVAD implant. Echocardiographic data included
V ejection fraction and dimensions, valvular insufficiency
graded as mild, moderate, moderate-severe, and severe
nsufficiency), and the presence of mild, moderate, or severe
V dysfunction. Right heart catheterizations were obtained
24 h before LVAD implant and before anesthesia induc-
ion. Hemodynamic data included measurements of right
trial (RA), pulmonary artery (PA), and pulmonary capillary
edge pressures. Cardiac output was assessed by thermodi-
ution. Systemic vascular resistance, transpulmonary gradi-
nt, pulmonary vascular resistance (PVR), and RV stroke
ork index (RVSWI) were calculated. In patients undergo-
ng extracorporeal right-sided circulatory support before
VAD implant, hemodynamic measurements were ob-
ained immediately before implantation of RV support.
Pre-operative laboratory data were obtained24 h before
urgery and included a complete blood count, liver enzymes,
Abbreviations
and Acronyms
AST  aspartate
aminotransferase
AUC  area under the
curve
CI  confidence interval
ECMO  extracorporeal
membrane oxygenation
iNO  inhaled nitric oxide
LV  left
ventricle/ventricular
LVAD  left ventricular
assist device
OR  odds ratio
PA  pulmonary artery
PVR  pulmonary vascular
resistance
RA  right atrial
RV  right
ventricle/ventricular
RVAD  right ventricular
assist device
RVFRS  right ventricular
failure risk score(s)
RVSWI  right ventricular
stroke work indexerum electrolytes, albumin, and coagulation parameters. Aatients requiring renal replacement therapy were assigned
creatinine of 6.0 mg/dl.
tatistical analysis. Data analysis was performed using SPSS
ersion 14.0 (SPSS Inc., Chicago, Illinois). Laboratory and
emodynamic data were evaluated as continuous and, as
ppropriate, dichotomous variables. Dichotomization of vari-
bles occurred at 25th (platelets, albumin), 50th (RVSWI, PA
ressure), or 75th percentiles (PVR, aspartate aminotransferase
AST], bilirubin, blood urea nitrogen, creatinine, white count).
ontinuous data were evaluated for normality, and between-
roup comparisons were performed using either the Student t
r the Mann-Whitney U test for normal and non-normal data,
espectively. Categorical data were compared with the Fisher
xact test for 2  2 tables or Pearson chi-square otherwise.
tepwise forward multivariable logistic regression analyses were
erformed on univariable predictors of RV failure (entry
riterion p  0.1). An RVFRS was devised by rounding the
xponentiated regression model coefficients to the nearest 0.5.
receiver-operating characteristic curve of the RVFRS was
reated, and the area under the curve (AUC) for the score was
alculated. The AUCs were also calculated for previously
ublished univariable predictors of RV failure (RA and PA
ystolic pressures, PVR, transpulmonary gradient, RVSWI,
nd severe RV failure on echocardiogram) (1,5–12). The AUC
or the RVFRS was then compared to each of the other AUCs
13). Kaplan-Meier survival curves were created to evaluate
ost-LVAD survival (defined as continued LVAD support at
he time of last follow-up, LVAD explant with survival 1
ear without repeat LVAD or transplant, or cardiac transplant)
nd, in those patients listed for transplant, freedom from death
n the transplant list. Survival between groups was analyzed by
og rank for linear trend. Unless otherwise specified, all data are
xpressed as mean  standard deviation.
This study was approved by the University of Michigan
edicine Institutional Review Board, and written informed
onsent was obtained before patient participation.
esults
here were 197 LVADs implanted during the period of
tudy, with 94% placed as a bridge to transplant and 6%
or destination therapy. Implanted pumps included the
eartMate 1000 IP (n  15, 8%), HeartMate VE (n  65,
3%), HeartMate XVE (n  77, 39%), HeartMate II (n 
8, 14%), Thoratec IVAD (n  7, 4%), Thoratec VAD
n  2, 1%) (all manufactured by Thoratec Corp, Pleasan-
on, California), Novacor ([n  1, 1%], WorldHeart Corp.,
akland, California) and Micromed ([n  2, 1%],
icroMed Cardiovascular Inc., Houston, Texas) devices.
ndications for LVAD included heart failure of nonischemic
n  95, 48%) or ischemic (n  102, 52%) etiologies.
hirty-six (35%) patients in the latter group had acute
schemic heart failure, 16 (44%) of whom developed shock
fter bypass surgery. Eight (4%) subjects required pre-
perative RV mechanical support (Abiomed BVS 5000).
n LV mechanical bridge was required in 45 (22%) and 55
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June 3, 2008:2163–72 Predicting Right-Sided Failure in LVAD Candidates28%) were supported with a pre-operative intra-aortic
alloon pump. Before LVAD implantation, 16 (8%) pa-
ients required renal replacement therapy and 47 (24%) were
n a ventilator.
Sixty-eight (35%) LVAD operations were complicated by
ost-operative RV failure. Right ventricular failure was diag-
osed based on the need for post-operative right-sided circu-
atory support in 29 (43%), prolonged post-operative inotropes
n 45 (69%), prolonged iNO in 33 (49%), and/or discharge to
ome on inotropes in 6 (9%). No patient met the definition of
V failure based solely on a home inotrope requirement. Four
atients (6%) met RV failure criteria because of an isolated
equirement for prolonged iNO. Of the 29 patients requiring
V circulatory support after LVAD implantation, 17 (59%)
eceived an Abiomed, 4 (14%) a Thoratec RVAD, and 8 (27%)
ere supported with ECMO.
Baseline Pre-Operative Clinical Demographics aOccurrence of RV Failure After LVAD Surgery for
Table 1 Baseline Pre-Operative Clinical DemOccurrence of RV Failure After LVA
RV Failure
(n  68)
Age, yrs 51.3 12.8
Male 51 (33)
Female 17 (42)
BSA, m2 1.93 0.21
BMI, kg/m2 26.6 4.8
Race
Caucasian 60 (37)
African American 7 (25)
Other 1 (17)
Etiology for heart failure
Ischemic 34 (33)
Nonischemic 34 (36)
NYHA functional class 4.0 0.0
III 0 (0)
IV 68 (35)
Diabetes mellitus () 13 (27)
Diabetes mellitus () 50 (35)
Hypertension () 21 (32)
Hypertension () 37 (31)
Hyperlipidemia () 23 (30)
Hyperlipidemia () 35 (33)
TIA/CVA () 9 (56)
TIA/CVA () 52 (30)
Prior sternotomy () 17 (25)
Prior sternotomy () 51 (40)
Blood type
O, n  79 24 (30)
A, n  86 35 (41)
B, n  22 5 (23)
AB, n  10 4 (40)
Reason for LVAD
Bridge to transplant 65 (35)
Destination therapy 3 (25)
Values are expressed as n (%) unless otherwise specified. Percents refl
*p value for between-group comparisons.
()  condition present; ()  condition absent; BMI  body ma
ventricular assist device; NYHA  New York Heart Association functional clas
attack/cerebrovascular accident.The presence of RV failure for each of the pre-operative
ecipient demographics and associated odds ratios (OR) for
nivariable predictors of RV failure with a p  0.1 are
hown in Table 1. Smaller body surface area, history of a
troke, and absence of a prior sternotomy were the only
emographic predictors of RV failure.
Table 2 depicts the pre-operative events and medical
nterventions that occurred in the LVAD sample. The odds
f RV failure were 2-fold higher in patients who experi-
nced an arrest at any time in the pre-operative period (p 
.03). The odds of RV failure were also higher in patients
eeding renal replacement therapy or ventilatory support
p  0.001). Subjects requiring a temporary mechanical LV
ridge before LVAD surgery had 3-fold higher odds of RV
ailure than those who did not, with 68% of patients on
CMO and 64% of patients with a Tandem Heart subse-
eh Variable
phics and the
gery for Each Variable
Failure
129) p Value*
Odds RV Failure
(95% CI)
 13.2 0.28
(67) 0.36
(59)
 0.24 0.063 3.39 (0.89–12.99)
 5.2 0.76
0.31
(63)
(75)
(83)
0.77
(67)
(64)
 0.1 0.55
(100)
(65)
(74) 0.30
(65)
(68) 1.00
(67)
(70) 0.75
(67)
(44) 0.048 2.99 (1.06–8.46)
(70)
(75) 0.041 0.49 (0.26–0.95)
(60)
0.32
(70)
(59)
(77)
(60)
0.55
(65)
(75)
values. Odds ratios are shown for univariable predictors with p 0.1.
x; BSA  body surface area; CI  confidence interval; LVAD  leftnd thEac
ogra
D Sur
No RV
(n 
49.2
105
24
2.0
26.8
103
21
5
68
61
4.0
2
127
36
93
45
81
54
72
7
121
52
77
55
51
17
6
120
9
ect row
ss inde
s at admission; RV  right ventricular; TIA/CVA  transient ischemic
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Predicting Right-Sided Failure in LVAD Candidates June 3, 2008:2163–72uently developing post-LVAD RV failure (p  0.001).
ost-cardiotomy shock was not associated with an increased
isk of RV failure.
The need for pre-operative mechanical extracorporeal
VAD support was not associated with increased risk of RV
ailure after LVAD placement (Table 2) (p  0.45). Of the
patients supported with a pre-operative RVAD, 4 expe-
ienced persistent RV failure during or after LVAD implan-
ation, of whom 3 required replacement of the RVAD at the
ime of LVAD implantation (mean duration of RVAD
upport after LVAD implant  11  9 days). One subject
xperienced recurrent RV failure, defined by the need for
rolonged inotropes (17 days) and inhaled iNO (4 days).
re-operative intravenous medications. Patients requir-
ng pre-operative intravenous vasopressor or antiarrhythmic
herapies were more likely to have RV failure after LVAD
mplantation (Table 3). Likewise, higher dose requirements
or vasopressin (p  0.001) and phenylephrine (p  0.018)
ere associated with RV failure. Right ventricular failure
Occurrence of RV Failure Basedon Pre-Operative Clinical Events and Medical In
Table 2 Occurrence of RV Failure Basedon Pre-Operative Clinical Events an
RV Failure
(n  68)
Code 24 h of admission () 10 (56)
Code 24 h of admission () 58 (32)
Code 24 h of admission () 16 (46)
Code 24 h of admission () 52 (32)
Code, any time pre-operative () 22 (48)
Code, any time pre-operative () 46 (31)
MI 1 week of LVAD () 15 (42)
MI 1 week of LVAD () 53 (33)
Pre-operative ICU stay () 65 (34)
Pre-operative ICU stay () 3 (60)
Length of pre-operative ICU stay, days 7.7 6.0
Post-cardiotomy shock () 9 (52)
Post-cardiotomy shock () 59 (33)
IABP () 22 (40)
IABP () 46 (32)
Life support ()† 35 (57)
Life support () 33 (24)
Bridge to bridge 25 (56)
None, n  152 43 (28)
ECMO, n  19 13 (68)
Abiomed, n  15 5 (33)
Tandem Heart, n  11 7 (64)
Time on bridge, days 5.5 2.6
Ventilator support () 26 (55)
Ventilator support () 42 (28)
Time on ventilator support, days 4.7 3.4
Renal replacement therapy () 13 (81)
Renal replacement therapy () 55 (30)
Pre-operative RVAD () 4 (50)
Pre-operative RVAD () 64 (34)
Values are expressed as n (%) unless otherwise specified. Percents refl
*p value for between-group comparisons. †Defined as need for ventila
ECMO  extracorporeal membrane oxygenation; IABP  intra-aortic
 right ventricular assist device (extracorporeal); other abbreviationseveloped less frequently in individuals supported with nilrinone and in those requiring higher milrinone doses (p
0.009), possibly reflecting poor tolerance of the vasodi-
atory properties of this agent in a patient sample with
verall increased vasopressor requirements.
re-operative echocardiography and cardiopulmonary
emodynamic measurements. In Table 4, pre-operative
chocardiographic and hemodynamic data are presented.
he only echocardiographic parameter that portended in-
reased odds of RV failure was the presence of severe RV
ystolic dysfunction (p  0.01). Patients with lower
VSWI, cardiac index, and PA systolic and mean pressures
ere more likely to develop RV failure (p  0.05). When
valuated categorically, a PA systolic pressure 50 mm Hg
p  0.035) and RVSWI 450 mm Hg·ml/m2 (p  0.012)
ere predictive of RV failure. The RA pressure, PVR, and
ranspulmonary gradient were not predictive of RV failure.
re-operative laboratory measurements. Table 5 depicts
re-operative laboratories. There were increased odds of RV
ailure in patients with higher blood urea nitrogen, creati-
ntions
dical Interventions
o RV Failure
(n  129) p Value*
Odds RV Failure
(95% CI)
8 (44) 0.067 2.61 (0.98–6.96)
121 (68)
19 (54) 0.18
110 (68)
24 (52) 0.035 2.09 (1.07–4.11)
105 (70)
21 (58) 0.42
108 (67)
127 (66) 0.34
2 (40)
7.4 6.9 0.37
8 (47) 0.11
121 (67)
33 (60) 0.32
96 (68)
26 (43) 0.005 4.20 (2.21–7.98)
103 (76)
20 (44) 0.001 3.17 (1.60–6.29)
109 (72) 0.32 (0.16–0.63)
6 (32)
10 (67)
4 (36.4)
5.3 2.5 0.85
21 (45) 0.001 3.18 (1.62–6.26)
108 (72)
5.5 3.0 0.32
3 (19) 0.005 9.93 (2.72–36.24)
126 (70)
4 (50) 0.45
125 (66)
values. Odds ratios are shown for univariable predictors with p 0.1.
al replacement therapy, or ECMO/Tandem Heart/Abiomed.
n pump; ICU  intensive care unit; MI  myocardial infarction; RVAD
ble 1.terve
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N
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tor, renine, glucose, white blood cell count, AST, and total
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June 3, 2008:2163–72 Predicting Right-Sided Failure in LVAD Candidatesilirubin, whereas the risk of RV failure was decreased in
atients with higher platelet counts (p  0.05 for each).
ategorical evaluation of the laboratory parameters revealed
ncreased odds of RV failure in patients with a creatinine
2.3 mg/dl (OR 5.56), blood urea nitrogen 48 mg/dl
OR 2.06), white blood cell count12.2 k/mm3 (OR 2.71),
latelet count 120 k/mm3 (OR 3.36), albumin 3.0 g/dl
OR 1.86), AST 80 IU/l (OR 3.20), and bilirubin 2.0
g/dl (OR 3.59) (all p  0.05).
VFRS. All clinical, echocardiographic, laboratory, and
emodynamic variables with a univariable p  0.1 for
redicting RV failure were entered into multivariable anal-
ses. Remaining independent (p  0.1) predictors of RV
ailure included a vasopressor requirement (OR 3.9, 95%
onfidence interval [CI] 1.5 to 9.8), AST 80 IU/l (OR
.1, 95% CI 0.96 to 4.5), bilirubin 2.0 mg/dl (OR 2.4,
5% CI 1.1 to 5.2), and creatinine 2.3 mg/dl (OR 2.9,
5% CI 1.1 to 7.7). These variables, therefore, were selected
s the components of the RVFRS. The RVFRS was
alculated as the sum of the points awarded for the presence
f each of the 4 pre-operative variables, with a vasopressor
Pre-Operative Intravenous Medication Requiremand Incidence of RV Failure After LVAD Implanta
Table 3 Pre-Operative Intravenous Medicatiand Incidence of RV Failure After LV
IV Support RV Failure
IV inotrope (),† 55 (32)
IV inotrope () 13 (48)
1 inotrope () 23 (32)
1 inotrope () 45 (36)
Milrinone () 30 (26)
dose, g/kg/min‡ 0.206 0.258 0
Milrinone () 39 (47)
Dobutamine () 19 (41)
dose, g/kg/min‡ 3.46 4.76
Dobutamine () 41 (35)
Dopamine () 19 (41)
dose, g/kg/min‡ 1.38 3.29
Dopamine () 50 (33)
Vasopressor (),§ 18 (67)
Vasopressor () 50 (29)
Norepinephrine () 4 (40)
dose, g/kg/min‡ 0.005 0.022 0
Norepinephrine () 64 (34)
Vasopressin () 10 (77)
dose, U/h‡ 0.529 1.37 0
Vasopressin () 58 (32)
Phenylephrine () 7 (64)
dose, g/min‡ 10.4 40.9
Phenylephrine () 61 (3)
IV antiarrhythmic () 19 (53)
IV antiarrhythmic () 49 (30)
Amiodarone () 10 (39)
Lidocaine () 3 (100)
Values are expressed as n (%) unless otherwise specified. Percents refl
*p value for between-group comparisons. †Inotrope defined as milri
§Vasopressor defined as phenylephrine, norepinephrine, or vasopress
IV  intravenous; other abbreviations as in Table 1.equirement assigned 4 points, AST 80 IU/l assigned 2 toints, bilirubin 2.0 mg/dl assigned 2.5 points, and
reatinine 2.3 mg/dl (or renal replacement therapy) as-
igned 3 points.
Applying the RVFRS in this sample (Table 6), the odds
f RV failure for patients (n  30) with an RVFRS 5.5
ere 15-fold greater than those (n  142) with an RVFRS
3.0, and about 3-fold greater than subjects (n  25) with
RVFRS of 4.0 to 5.0. Of the 129 patients who did not
evelop RV failure, 113 had an RVFRS 3.0 (specificity 
8%); the absence of RV failure was correctly identified in
13 of 142 patients with an RVFRS 3.0 (negative pre-
ictive value  80%). Among 68 patients with RV failure,
n RVFRS 5.5 identified 24 (sensitivity  35%). How-
ver, 24 of 30 patients with an RVFRS 5.5 developed RV
ailure (positive predictive value  80%).
The AUC for the RVFRS (Fig. 1) was 0.73  0.04.
eceiver-operating characteristic curves were also gener-
ted for commonly used predictors of RV failure, includ-
ng RVSWI, transpulmonary gradient, PVR, RA, and
A systolic pressures, and severe RV failure on echocar-
iography (Fig. 1, Table 7) (1,5,7–12). Comparison of
quirements
mplantation
Failure p Value*
Odds RV Failure
(95% CI)
(68) 0.13
(52)
(69) 0.54
(64)
(74) 0.004 0.40 (0.22–0.72)
 0.251 0.009 0.22 (0.065–0.72)
(53)
(59) 1.00
 3.85 0.38
(65)
(59) 0.37
 1.72 0.27
(67)
(33) 0.005 4.80 (2.02–11.41)
(71)
(60) 0.74
 0.022 0.72
(66)
(23) 0.002 7.24 (1.92–27.30)
 0.590 0.001 1.72 (1.15–2.56)
(69)
(36) 0.050 3.59 (1.01–12.72)
 22.6 0.018 1.01 (0.997–1.018)
(67)
(47) 0.019 2.56 (1.22–5.33)
(70)
(62)
(0)
values. Odds ratios are shown for univariable predictors with p 0.1.
obutamine, or dopamine. ‡Untreated patients assigned dose of zero.entstion
on Re
AD I
No RV
115
14
50
79
86
.302
43
26
2.62
77
26
0.76
103
9
120
6
.004
123
3
.074
126
4
3.8
125
17
112
16
0
ect row
none, dhe AUC of the RVFRS with that of the other previously
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Predicting Right-Sided Failure in LVAD Candidates June 3, 2008:2163–72dentified predictors shows that the RVFRS is a more
iscriminative predictor of RV failure (all p  0.05).
urvival and RVFRS. During the 180  236 days of
ollow-up, 4 (2%) patients were permanently weaned from
VAD support without death or transplant, 17 (9%) re-
ained supported, 39 (20%) died, and 137 (70%) were
Echocardiographic and Cardiopulmonary HemodMeasurements Before LVAD Implantation With A
Table 4 Echocardiographic and CardiopulmoMeasurements Before LVAD Implan
RV F
Echocardiographic parameters
LViDd, mm 67.1
LViDs, mm 60.8
Mitral regurgitation severity† 2.0
Tricuspid regurgitation severity† 1.7
Aortic insufficiency severity† 0.2
Ejection fraction, % 13.6
Left ventricular mass, g 332.9
RV dysfunction, n (%)
None, n  30 8 (
Mild, n  36 12 (
Moderate, n  58 16 (
Severe, n  69 32 (
Electrocardiogram
Rhythm, n (%)
Sinus, n  128 41 (
Paced, n  41 14 (
Afibrillation/flutter, n  28 13 (
QRS, ms 144.4
Vital signs
Temperature,°C 37.3
Systolic blood pressure, mm Hg 96.9
Diastolic blood pressure, mm Hg 62.0
Mean arterial pressure, mm Hg 73.6
Heart rate, beats/min 93.6
Cardiopulmonary hemodynamics
Right atrial pressure, mm Hg 12.5
Mean PA pressure, mm Hg 30.5
PA systolic pressure, mm Hg 45.2
50 22 (
50 41 (
PA diastolic pressure, mm Hg 23.2
Pulmonary capillary wedge pressure, mm Hg 22.2
Cardiac index, l/min/m2 2.1
Systemic vascular resistance, dynes·s·cm5 1,334
Pulmonary vascular resistance, WU 2.3
2.8 22 (
2.8 40 (
Transpulmonary gradient, mm Hg 8.3
PA input resistance 15.0
RVSWI, mm Hg·ml/m2 404
450 40 (
450 23 (
Percents reflect row values. Odds ratios are shown for univariable
insufficiency graded on a 4-point scale (1mild, 2moderate, 3m
RV failure on pre-operative echocardiography.
LViDd  left ventricular internal diastolic diameter; LViDs  left ve
ventricular stroke work index; WU  Wood units; other abbreviationsransplanted. Twenty-six (38%) patients with post- sperative RV failure died compared with 13 (10%) without
omplicating RV failure (OR death 5.5, 95% CI 2.6 to
1.8). Of these deaths, 21 (81%) and 6 (46%), respectively,
ccurred in the operating room. Figure 2 depicts the
aplan-Meier survival curves for the high (RVFRS 5.5),
edium (RVFRS 4.0 to 5.0), and low (RVFRS 3.0) risk
iciated RV Failure
Hemodynamic
n With Associated RV Failure
No RV Failure p Value*
Odds RV Failure
(95% CI)
70.1 11.1 0.12
62.5 12.4 0.42
2.1 1.5 0.97
1.4 1.1 0.10 1.25 (0.97–1.61)
0.2 0.7 0.91
13.6 5.4 0.85
.1 360.6 138.6 0.20
0.067
22 (73%)
24 (67%)
42 (72%)
37 (54%) 0.012 2.21 (1.20–4.07)‡
0.35
87 (68%)
27 (66%)
15 (54%)
131.8 44.8 0.82
37.2 0.6 0.16
99.1 15.6 0.33
61.3 11.4 0.68
74.0 11.3 0.85
92.6 18.0 0.72
11.9 5.8 0.62
33.5 9.2 0.040 0.97 (0.94–0.99)
49.9 14.6 0.036 0.98 (0.96–0.99)
66 (75%) 0.030 0.49 (0.56–0.91)
60 (59%)
25.3 7.6 0.082 0.97 (0.93–1.00)
23.7 7.9 0.21
2.3 0.6 0.049 0.61 (0.37–1.00)
1,180 382 0.11
2.3 1.5 0.96
38 (63%) 0.51
88 (70%)
9.8 5.6 0.13
16.1 7.5 0.79
555 318 0.002
54 (57%) 0.009 2.32 (1.24–4.32)
72 (76%)
rs with p  0.1. *p value for between-group comparisons. †Valve
te-severe, 4 severe). ‡Odds of post-operative RV failure with severe
r internal systolic diameter; PA  pulmonary artery; RVSWI  right
ble 1.ynamssoc
nary
tatio
ailure
 12.7
 13.2
 1.3
 1.2
 0.7
 6.8
 103
27%)
33%)
28%)
46%)
32%)
34%)
46%)
 43.6
 0.9
 13.7
 13.4
 11.3
 16.4
 6.3
 9.3
 14.4
25%)
41%)
 7.5
 7.3
 0.6
 546
 1.6
37%)
30%)
 4.4
 8.0
 275
43%)
24%)
predicto
oderacore strata. The 180-day post-LVAD survivals were 66 
9
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June 3, 2008:2163–72 Predicting Right-Sided Failure in LVAD Candidates%, 80  8%, and 90  3% for the high, medium, and low
VFRS strata, respectively, with a log rank for linear trend
 0.0045, showing the increased mortality risk associated
ith higher RVFRS.
In those individuals (n  185) bridged to transplant with
n LVAD, freedom from death on the transplant list was
4  11% and 89  5% for patients with (n  65) and
ithout (n  120) RV failure, respectively, at 1 year (p 
Pre-Operative Laboratory Values and Associated
Table 5 Pre-Operative Laboratory Values an
RV Failure
Sodium, mEq/l 134 7
Potassium, mEq/l 4 1
Bicarbonate, mEq/l 27 5
Blood urea nitrogen, mg/dl 43 26
48 24 (47%)
48 44 (30%)
Creatinine, mg/dl 2.4 1.8
2.3 20 (69%)
2.3 49 (29%)
Glucose, mg/dl 149 60
White blood cell count, k/mm3 12 5
12.2 26 (52%)
12.2 42 (29%)
Hemoglobin, g/dl 12 2
Platelets, k/mm3 165 84
120 27 (56%)
120 41 (28%)
Total protein, g/dl 6.3 1.1
Albumin, g/dl 3.1 0.7
3.0 33 (43%)
3.0 35 (29%)
LDH, IU/l 488 340
AST, IU/l 96 96
80 27 (55%)
80 41 (28%)
ALT, IU/l 128 200
Alkaline phosphatase, IU/l 119 64
Total bilirubin, mg/dl 3.2 4.5
2.0 27 (57%)
2.0 41 (27%)
INR, s 1.2 0.2
PTT, s 45.7 19.0
Percents reflect row values. Odds ratios are shown for univariable pre
ALT alanine aminotransferase; AST aspartate aminotransferase
acid dehydrogenase; PTT  partial thromboplastin time; other abbrev
ight Ventricular Failure Risk Scorend Lik lihood of RV Failure by Score Strata
Table 6 Right Ventricular Failure Risk Scoreand Likelihood of RV Failure by Score Strata
Risk Score n
RV Failure
(n)
No RV
Failure (n)
Likelihood Ratio
(95% CI)
3.0 142 29 113 0.49 (0.37–0.64)
4.0–5.0 25 15 10 2.8 (1.4–5.9)
5.5 30 24 6 7.6 (3.4–17.1)
isk Score is derived by summing points awarded for the presence of a vasopressor requirement
4 points), AST 80 IU/l (2 points), bilirubin 2.0 mg/dl (2.5 points), and creatinine 2.3 mg/dla
3 points).
Abbreviations as in Table 1..005). Freedom from death on the transplant list for high,
edium, and low strata RVFRS was 66  9%, 53  22%,
nd 85  5%, respectively, at 1 year (log rank p  0.002).
iscussion
ight ventricular failure after LVAD surgery is associated
ith increased post-operative morbidity and mortality.
owever, criteria for RV support are poorly defined because
efinitions of RV failure vary and its prediction is difficult
14). Using extensive information from a prospectively
ollected LVAD database, we created an RVFRS that
tratifies an LVAD candidate’s risk of RV failure and
ost-operative death. The RVFRS is composed of nonin-
asive, routinely collected clinical pre-operative data, pro-
iding critical patient-specific operative morbidity and mor-
ality estimates that are invaluable during the pre-operative
atient/family education encounter. Although more evalu-
-Operative RV Failure
ociated Post-Operative RV Failure
V Failure p Value*
Odds RV Failure
(95% CI)
 6 0.44
 1 0.69
 4 0.25
 17 0.001 1.03 (1.01–1.04)
7 (53%) 0.040 2.06 (1.07–3.96)
2 (70%)
 0.9 0.005 1.68 (1.30–2.18)
(31%) 0.005 5.56 (2.36–13.06)
0 (71%)
 45 0.039 1.007 (1.001–1.013)
 3 0.005 1.15 (1.06–1.25)
4 (48%) 0.003 2.71 (1.40–5.24)
5 (71%)
 2 0.94
 88 0.001 0.99 (0.99–1.00)
1 (44%) 0.005 3.36 (1.71–6.59)
7 (72%)
 0.9 0.23
 0.6 0.055 0.64 (0.40–1.01)
3 (57%) 0.046 1.86 (1.02–3.40)
5 (71%)
 410 0.005 1.001 (1.000–1.002)
 169 0.005 1.00 (0.999–1.003)
2 (45%) 0.001 3.20 (1.64–6.25)
7 (72%)
 160 0.16
 48 0.15
 0.8 0.005 1.68 (1.29–2.19)
0 (43%) 0.005 3.59 (1.82–7.10)
9 (73%)
 0.3 0.38
 20.2 0.16
with p  0.1. *p value for between-group comparisons.
International normalized ratio of the prothrombin time; LDH lactic
as in Table 1.Post
d Ass
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133
4
27
32
2
10
1.5
9
12
131
9
2
10
12
206
2
10
6.5
3.3
4
8
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73
2
10
84
106
1.2
2
10
1.2
43.5
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Predicting Right-Sided Failure in LVAD Candidates June 3, 2008:2163–72f those patients who may benefit from planned biventricu-
ar support. Further, because present options for permanent
iventricular support offer limited mobility and quality of
ife, the RVFRS may assist in identifying poor candidates
or permanent LVAD support. In this analysis, the desti-
ation therapy sample was small (n  12) and more studies
ill be needed to clarify the model’s role in this population.
Because various mechanisms underlie the development of
V failure after LVAD implantation (i.e., increased after-
oad, pre-load, ventricular interdependence, RV ischemia),
easures reflective of the consequences of RV dysfunction,
ather than diagnostic of poor RV contractility, are likely to
Figure 1 ROC Curve of the RVFRS and
Other Univariable Predictors of RV Failure
Table 7 shows the areas under the receiver-operating characteristic (ROC)
curve for the predictors. PAS  pulmonary artery systolic; PVR  pulmonary
vascular resistance; RA  right atrial; RV  right ventricular; RVFRS  right
ventricular failure risk score; RVSWI  right ventricular stroke work index; TPG
 transpulmonary gradient.
rea Under the Receiver-Operating Characteristicurve of the RV Failure Risk Score and Othomm nly Us d Predictor of RV Failure
Table 7
Area Under the Receiver-Operating Characteristic
Curve of the RV Failure Risk Score and Other
Commonly Used Predictors of RV Failure
AUC (95% CI) *p Value
RV failure risk score 0.73 (0.65–0.81) —
Severe RV failure on echocardiograph 0.59 (0.51–0.68) 0.004
RVSWI 0.63 (0.55–0.72) 0.011
PVR 0.50 (0.41–0.59) 0.001
TPG 0.56 (0.48–0.65) 0.001
PA systolic pressure 0.59 (0.51–0.68) 0.017
RA pressure 0.53 (0.44–0.61) 0.001
p value comparing the AUC of the RV Failure Risk Score to that of the respective predictor.L
AUC  area under the curve; PVR  pulmonary vascular resistance; RA  right atrial; TPG 
ranspulmonary gradient; other abbreviations as in Tables 1 and 4.e most useful in predicting RV failure. Although other
tudies have identified many pre-operative variables associ-
ted with post-operative RV failure (1,2,4–12), data are
imited by an ambiguous definition (4) or low prevalence of
V failure (5,7,10) and exclusion of patients with normal
re-operative RV ejection fractions (6). Furthermore, many
rior studies relied solely on univariable analyses (2,4–
,11). Multivariable techniques, as used in this study, afford
imultaneous evaluation of many risk factors that, when
valuated separately, may suggest different outcomes for an
ndividual patient (15).
Several intuitively appealing pre-operative hemodynamic
nd laboratory parameters have been associated with in-
reased risk of RV failure, including reduced RVSWI
5,7,10,12) or PA pressure (5,7,10,11), and elevated RA
ressure (1,8,9), AST (5,11), bilirubin (2,4,6), and creati-
ine (4,6,11). Elevations in RV afterload and pre-load with
eductions in RV contractility are reflected in hemodynamic
easurements, whereas renal and hepatic laboratory abnor-
alities reflect congestion and hypoperfusion in those with
V dysfunction. Pre-operative elevation of RA pressure was
redictive of RV failure in 2 retrospective analyses (1,9), but
ubsequent studies (including ours) have not validated this
isk (2,4–6,11). Fukamachi et al. (5) analyzed pre-operative
isks for RV failure occurring in 11 of 100 HeartMate 1000
P and VE patients. Increased AST and lower mean PA
ressure and RVSWI were associated with increased risk of
V failure (5). Likewise, Kavarana et al. (2) evaluated 69
Figure 2 Kaplan-Meier Survival Curve
for Each RV Failure Risk Score Strata
The 180-day post-left ventricular assist device survival curves
for each score strata are displayed. RV  right ventricular.VAD patients (21 with RV failure) and found that higher
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June 3, 2008:2163–72 Predicting Right-Sided Failure in LVAD Candidatesre-operative bilirubin was a significant predictor of RV
ailure, whereas lower RVSWI and higher AST achieved a
onsignificant predictive trend. In the current study, all of
he previously mentioned variables were associated with
ignificantly increased risk for RV failure, but only AST and
ilirubin remained independently predictive after multiva-
iable analysis. When the AUC of the RVFRS was com-
ared with that of previously published predictors (1,5,7,9–
2) of RV failure, the RVFRS showed superior risk
iscrimination.
As previously highlighted by Kormos et al. (6), it is likely
hat nonhemodynamic pre-operative clinical factors are
ore predictive of RV failure than inherent measurements
f RV function. Several univariable clinical predictors for
V failure have been previously identified, including female
ender, smaller body surface area, nonischemic etiology of
ardiomyopathy, and pre-operative circulatory or inotropic
upport (1,4–7,10). In our sample, over 40 clinical param-
ters were analyzed, but only a pre-operative vasopressor
equirement remained independently predictive of RV fail-
re. Of the 4 variables in the RVFRS, a vasopressor
equirement has the greatest weight (4 points), reflecting
he importance of underlying pre-operative hemodynamic
nstability in the pathophysiology of RV failure.
Consistent with previous studies (1,4–7), the presence of
V failure in this sample was associated with nearly 6-fold
igher odds of post-operative LVAD death. Overall survival
ecreased with increasing RVFRS strata. Likewise, in the
ridge-to-transplant group, survival to transplant was lower
or subjects with higher RVFRS. Thus, in addition to
dentifying patients at high risk for post-LVAD RV failure,
he RVFRS identified subjects at higher risk for post-
perative death and those less likely to survive to transplant.
tudy limitations. Our patient sample had clinical charac-
eristics and a prevalence of RV failure similar to those
eported for other cohorts (1,2,16). However, cohort studies
re subject to bias and confounding that may have influ-
nced our results. We tried to adjust for confounding
ariables through multivariable analysis, but it is unlikely
hat all confounders were identified. Furthermore, there is
o means of identifying and adjusting for all the patient
election biases involved with LVAD candidacy and referral
n an unblinded evaluation. Because this is a single-center
tudy, study power was limited. However, this is the largest
ohort of LVAD subjects analyzed with RV failure.
ecause of sample-size limitations, we used a p  0.1 as
ariable selection criteria in RVFRS development. We
ecognize that the use of a less rigorous standard may affect
uture validation of the model. Of the 68 cases of RV
ailure, 58 occurred in first-generation HeartMate devices,
ith only 3 occurring in nonpulsatile LVADs. Thus, testing
f the RVFRS in an independent patient sample with a
ariety of devices is necessary.
Another weakness of post-LVAD RV failure studies is
he lack of a uniform definition for RV failure. Our
iagnosis was predicated on the medical judgment of the sreating physician, which is likely to vary between providers.
ecause every attempt was made to include all patients
xperiencing RV failure in the post-operative period, the
efinition of RV failure was broader in this study than in
thers that only included patients requiring RVAD
ssistance—the most extreme form of RV dysfunction
4,5,7,10). Prolonged inotrope support is known to be
ssociated with increased morbidity and/or mortality in
atients with post-LVAD RV dysfunction, independent of
VAD requirements (2,6,12). We prospectively selected
14 days of inotrope support as an RV failure criterion in
n attempt to identify those patients with clinically relevant
V dysfunction, requiring inotropes for additional RV
upport outside of that which is usual in the early post-
perative period. This definition was consistent with that
sed in prior studies (1,2) and was the inotrope criterion
sed by the Interagency Registry of Mechanically Assisted
irculatory Support until 2007 (17).
The need for home inotropes was included prospectively
n the RV failure definition to identify patients with a
elayed presentation of RV failure. No patient met the
efinition of RV failure based on this criterion alone, and its
nclusion in the definition of RV failure in future studies
arrants reexamination.
Last, prolonged iNO administration was a defining
riterion because it is used by many as a hemodynamic
ridge after LVAD placement. Nitric oxide has been shown
o reduce PA pressures and improve LVAD flow in the
etting of RV dysfunction (18), reducing the need for
echanical RV support (16). In this study, all but 4 patients
n prolonged iNO met other inclusion criteria for RV
ailure, mainly a need for prolonged inotrope therapy.
owever, despite being on an inotrope, 2 patients on
rolonged iNO died of RV failure before reaching the
4-day inotrope requisite and would not have been properly
ategorized in this analysis otherwise.
We did not exclude patients with pre-LVAD extracorporeal
V support. In these 8 patients, pre-operative extracorporeal
VAD support did not predict the development of post-
VAD RV failure, with 4 RVADs successfully explanted at
he time of LVAD operation. This may reflect the benefit of
educed RV afterload and pre-load after LVAD placement in
elect individuals. In a separate analysis, exclusion of these 8
atients did not affect the discriminative ability of the RVFRS
o predict RV failure (data not shown).
The RVFRS offers a high specificity for excluding RV
ailure and may be useful when devising an operative strategy
or LVAD candidates, especially in those individuals with high
VFRSs. However, RV failure occurred in 20% of patients in
he lowest strata (RVFRS 3), so we were unable to identify
truly low-risk group of patients. The RVFRS is one of several
actors that physicians can consider in the complex evaluation
f LVAD candidacy and operative risk. As with all clinical
ools, the RVFRS is not meant to replace, but rather should
upplement clinical judgment.
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Predicting Right-Sided Failure in LVAD Candidates June 3, 2008:2163–72onclusions
n conclusion, the RVFRS is the first model for pre-
perative risk stratification of RV failure in LVAD candi-
ates. The RVFRS is composed of easily obtained pre-
perative clinical and laboratory data, and offers a high
pecificity for excluding the occurrence of RV failure after
VAD implant. Higher RVFRS in this sample also iden-
ified individuals at an increased risk of post-operative
eath. Validation of this model in an independent sample
sing a variety of devices and candidates is warranted before
t is widely implemented.
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